Biodel Company Profile (NASDAQ:ALBO)

About Biodel (NASDAQ:ALBO)

Biodel logoBiodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALBO
  • CUSIP: N/A
  • Web:
  • Market Cap: $249.96 million
  • Outstanding Shares: 8,882,000
Average Prices:
  • 50 Day Moving Avg: $23.31
  • 200 Day Moving Avg: $22.40
  • 52 Week Range: $14.00 - $37.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.12
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.27 million
  • Price / Sales: 75.67
  • Book Value: $8.49 per share
  • Price / Book: 3.28
  • EBITDA: ($18,880,000.00)
  • Current Ratio: 8.64%
  • Quick Ratio: 8.64%
  • Average Volume: 18,625 shs.
  • Beta: 1.43
  • Short Ratio: 1.32

Frequently Asked Questions for Biodel (NASDAQ:ALBO)

What is Biodel's stock symbol?

Biodel trades on the NASDAQ under the ticker symbol "ALBO."

How were Biodel's earnings last quarter?

Biodel Inc. (NASDAQ:ALBO) announced its quarterly earnings results on Monday, August, 21st. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.02. View Biodel's Earnings History.

Where is Biodel's stock going? Where will Biodel's stock price be in 2017?

5 analysts have issued 1 year target prices for Biodel's stock. Their forecasts range from $35.00 to $58.00. On average, they expect Biodel's stock price to reach $46.50 in the next twelve months. View Analyst Ratings for Biodel.

Who are some of Biodel's key competitors?

How do I buy Biodel stock?

Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biodel's stock price today?

One share of Biodel stock can currently be purchased for approximately $27.86.

MarketBeat Community Rating for Biodel (NASDAQ ALBO)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biodel (NASDAQ:ALBO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $46.50 (66.91% upside)
Consensus Price Target History for Biodel (NASDAQ:ALBO)
Price Target History for Biodel (NASDAQ:ALBO)
Analysts' Ratings History for Biodel (NASDAQ:ALBO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017WedbushReiterated RatingOutperform$58.00LowView Rating Details
8/16/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
7/18/2017Needham & Company LLCInitiated CoverageBuy -> Buy$35.00HighView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
1/25/2017William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Biodel (NASDAQ:ALBO)
Earnings by Quarter for Biodel (NASDAQ:ALBO)
Earnings History by Quarter for Biodel (NASDAQ ALBO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/20176/30/2017($0.84)($0.86)ViewN/AView Earnings Details
5/10/2017Q2 2017($1.11)($1.06)ViewN/AView Earnings Details
8/11/2016Q216($0.05)ViewN/AView Earnings Details
5/9/2016Q2($0.04)($0.09)ViewN/AView Earnings Details
2/16/2016Q1($0.08)($0.05)ViewN/AView Earnings Details
12/17/2015Q315($0.11)($0.05)ViewListenView Earnings Details
8/13/2015Q3($0.10)($0.12)ViewListenView Earnings Details
5/6/2015Q215($0.23)($0.27)ViewN/AView Earnings Details
2/12/2015Q115($0.18)($0.20)ViewN/AView Earnings Details
12/17/2014Q414($0.27)($0.16)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.26)($0.15)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.29)ViewN/AView Earnings Details
2/6/2014Q4($0.19)($0.20)ViewN/AView Earnings Details
12/18/2013Q4($0.30)($0.04)ViewListenView Earnings Details
8/12/2013Q3 2013($0.37)($0.66)ViewN/AView Earnings Details
5/8/2013Q2 2013($0.43)($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biodel (NASDAQ:ALBO)
2017 EPS Consensus Estimate: ($3.37)
2018 EPS Consensus Estimate: ($3.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.91)($0.91)($0.91)
Q2 20171($0.87)($0.87)($0.87)
Q3 20172($0.79)($0.76)($0.78)
Q4 20172($0.86)($0.77)($0.82)
Q1 20181($0.76)($0.76)($0.76)
Q2 20181($0.76)($0.76)($0.76)
Q3 20181($0.77)($0.77)($0.77)
Q4 20181($0.77)($0.77)($0.77)
(Data provided by Zacks Investment Research)


Dividend History for Biodel (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biodel (NASDAQ:ALBO)
Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 27.36%
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/20/2013Brian Jg PereiraDirectorSell4,734$2.26$10,698.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biodel (NASDAQ:ALBO)
Latest Headlines for Biodel (NASDAQ:ALBO)
Loading headlines, please wait.



Biodel (ALBO) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.